Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that investing in the right stock at the right time -- and holding onto it for a while - ...

Eli Lilly and other drugmakers are reportedly planning to urge the Trump administration to pause Medicare drug-price ...

Each brand has its own formula for helping users achieve their weight loss goals. Their methods include remote healthcare ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

Three GLP-1 drugs are best at helping obese and overweight people drop weight, including one that hasn’t yet been ap ...

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective ...

About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the ...

The U.S. Food and Drug Administration (FDA) has granted approval for Zepbound, a weight-loss medication, to treat moderate to severe obstructive sleep apnea (OSA) in individuals with obesity.